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EPIDEMIOLOGY
Survival in Patients With Uveal Melanoma in Europe
Gianni Virgili, MD; Gemma Gatta, MD; Laura Ciccolallo, MSc; Riccardo Capocaccia, MSc;
Annibale Biggeri, MD; Emanuele Crocetti, MD; Jean-Michel Lutz, MD; Eugenio Paci, MD;
for the EUROCARE Working Group
Objective: To estimate survival in patients in whom uveal
melanoma was diagnosed between January 1, 1983, and
December 31, 1994, in Europe.
Methods: Survival analysis of data from 32 cancer reg-
istries in 16 European countries adhering to the Euro-
pean Cancer Registry for 5788 patients with uveal mela-
noma diagnosed between January 1, 1983, and December
31, 1994, with follow-up to 1999.
Results: Five-year relative survival was 68.9% overall and
remained stable with the period of diagnosis. Relative ex-
cess risk of death was 2.45 (95% confidence interval [CI],
2.10-2.86) in patients aged 75 years or older compared with
patients aged 54 years or younger and was slightly higher
in male patients (relative excess risk, 1.10; 95% CI, 1.02-
1.19) than in female patients. Survival was similar in Nor-
dic countries (relative excess risk, 1.03; 95% CI, 0.87-
1.21) compared with the United Kingdom (reference
country) and was lower in eastern and western European
countries (1.26; 1.05-1.52, and 1.25; 0.90-1.60, respec-
tively) compared with the reference country.
Conclusions: In this large series of patients with uveal
melanoma, 5-year relative survival remained stable with the
introduction of conservative treatment in individuals in
whom uveal melanoma was diagnosed between 1983 and
1994. We found differences in survival between sexes and
in European areas that should be investigated in studies
that consider tumor characteristics at the individual level.
Arch Ophthalmol. 2008;126(10):1413-1418
T REATMENTS OF UVEAL MELA-noma have changed with theprogressive introduction ofconservative managementfor smaller tumors during
the 1980s.1,2 Despite this therapeutic shift,
5-year relative survival (ie, the ratio of sur-
vival in patients with cancer to the sur-
vival expected from mortality in the gen-
eral population) was reported to be stable
at a level of approximately 80% of patients
in a recent study based on the National Can-
cer Institute Surveillance, Epidemiology,
and End Results (SEER) registries and con-
ducted in the United States.1 This 5-year rate
is consistent with the results from the Col-
laborative Ocular Melanoma Study
(COMS),3 which found a similar survival
rate after either enucleation or radiola-
beled iodine 125 brachytherapy for me-
dium-sized uveal melanomas.
The European Cancer Registry
(EUROCARE)–based study of survival and
care of patients with cancer, including data
from 67 cancer registries with a com-
bined population of 100 million persons
in 22 European countries, offers a unique
opportunity to study the epidemiology of
rare cancers in a continental population.
We recently reported the incidence of uveal
melanoma using cancer registry data col-
lected in the framework of the EUROCARE
project from January 1, 1983, to Decem-
ber 31, 1994.4 In the present study, we es-
timated survival and its possible tempo-
ral, demographic, and geographic variation
in patients with uveal melanoma in the
same cohort.
METHODS
DEFINITIONS AND
INCLUSION CRITERIA
We analyzed data from 32 cancer registries for
patients aged 15 to 99 years with a diagnosis
of a selected rare cancer between 1983 and
1994. These data were from 16 European coun-
tries participating in EUROCARE.
Cases were defined as patients with ocular
melanoma as identified by International Clas-
sification of Diseases, Ninth Revision (ICD-9) to-
pography codes 190.0 (iris and ciliary body),
190.5 (retina), and 190.6 (choroid) and by In-
ternational Classification of Diseases for Oncol-
ogy morphology codes 8720 to 8780 (uveal
melanoma). Based on the suggestion of Stang
CME available online at
www.jamaarchivescme.com
and questions on page 1335
Author Affiliations:
Departments of
Oto-Neuro-Ophthalmological
Surgical Sciences (Dr Virgili)
and Statistics “G. Parenti”
(Dr Biggeri), University of
Florence, and the Biostatistics
Unit (Dr Biggeri) and the
Clinical and Descriptive
Epidemiology Unit
(Drs Crocetti and Paci), Center
for Study and Prevention of
Cancer, Scientific Institute of
the Tuscany Region, Florence;
the Epidemiology Unit, Istituto
Nazionale per lo Studio e la
Cura dei Tumori, Milan
(Dr Gatta and Ms Ciccolallo);
Laboratory of Epidemiology,
Istituto Superiore di Sanità,
Rome (Mr Capocaccia), Italy;
and Registre Genevois des
Tumeurs, Geneva, Switzerland
(Dr Lutz).
Group Information: A complete
list of the members of the
EUROCARE Working Group
appears at the end
of this article.
(REPRINTED) ARCH OPHTHALMOL / VOL 126 (NO. 10), OCT 2008 WWW.ARCHOPHTHALMOL.COM
1413
©2008 American Medical Association. All rights reserved.
Downloaded From:  by a London Sch of Hygiene & Tropical Medicine User  on 05/09/2018
et al5 and on an incidence study conducted by us in this same
cohort,4 we also included tumors with unspecified location
(ICD-9 code 190.9, part unspecified).
Contributing registries provided patient demographic data
and vital statistics for 1983 to 1994 with follow-up to 1999.
Table 1 gives the registries and the number of cases for each.
Verification of the diagnosis was classified as microscopic, clini-
cal, or unknown. Microscopic verification is obtained when the
eye is enucleated, whereas it can reasonably be assumed that
the eye is treated conservatively with radiotherapy when the
diagnosis is clinical. The number of tumors with unknown di-
agnostic verification was low (2.6%); thus, they were pooled
with those clinically verified. Data were provided by 32 cancer
registries (Table 1) in 16 countries. Because these countries dif-
fer noticeably in terms of economic development, social struc-
ture, and health care structure, we defined 4 geographic groups
within which survival after common cancers are much the
same6-9: United Kingdom; western Europe; eastern Europe; and
the Nordic or Scandinavian area including Iceland. Data from
the Scotland registry were eliminated as requested by the reg-
istry because of suspected undetected loss to follow-up. There-
fore, the UK area includes only registries in England and Wales.
Only first occurring cancers at any site, as defined by Inter-
national Classification of Diseases for Oncologymorphology fifth-
digit behavior code 3, were included in survival analyses. Both
microscopically verified and nonverified cases were included,
but cases known to registries by death certificate only or dis-
covered incidentally at autopsy were excluded. Further de-
tails of the EUROCARE data set are available elsewhere.6-9
STATISTICAL ANALYSES
OF RELATIVE SURVIVAL
Univariate 5-year relative survival obtained using SEER*Stat
software (National Cancer Institute, Bethesda, Maryland)10 is
reported. For multivariate analysis of relative survival, we fol-
lowed the approach for grouped data suggested by Hakulinen11
and Dickman et al.12 A relative survival model was used in the
framework of generalized linear models to assess the effect of
temporal, demographic, and geographic variables on risk of death
to compute relative excess risk (RER) for categories of the same
variable. The correlation of the data within registry was taken
into account using a robust variance estimator.13,14 Relative ex-
cess risk has also been referred to as excess hazard ratio and
can be considered the excess hazard owing to diagnosis of can-
cer once the known baseline hazard, mortality in the general
population, has been taken into account. Age was coded cat-
egorically in 3 bands in these models: 15 to 54 years, 55 to 74
years, and 75 years or older.
After temporal, demographic, and geographic variables were
included in the regression model, the covariates coding for the
type of diagnosis verification (microscopic vs clinical or un-
known) and the tumor subsite were introduced into the model.
Subsite was coded as typical uveal melanoma location (ICD-9
codes 190.0, 190.5, and 190.6) or unspecified eye and orbit mela-
noma location (ICD-9 code 190.9). Statistical analyses were made
using commercially available software (STATA version 9.2;
StataCorp LP, College Station, Texas).
RESULTS
Vital statistics for 5 years from diagnosis of uveal mela-
noma were obtained for 5788 incident melanomas dur-
ing the 12 years of the study (1983-1994). Of the inci-
dent cohort of 6121 patients, 326 were excluded because
they had other malignant lesions at baseline (n=269) or
the diagnosis was made on the basis of the death certifi-
cate only (n=57). Seven additional patients were lost to
follow-up.
UNIVARIATE ANALYSES
OF 5-YEAR RELATIVE SURVIVAL
Table 2 gives the number of cases and 5-year relative
survival by age, sex, period, geographic area, type of di-
agnosis verification, subsite, and year of follow-up. As
expected, survival decreased with age and was lower in
patients with tumors examined microscopically, which
is a proxy of enucleation and, thus, of larger tumor size.
Worse survival was also found for tumors with unspeci-
fied ocular subsite (ICD-9 code 190.9). No substantial
temporal trend could be identified; however, there were
differences among geographic areas, with the UK and Nor-
dic regions demonstrating better survival than the west-
ern and eastern European regions. Table 3 gives 5-year
relative survival rates for geographic areas across peri-
ods of diagnosis, which do not suggest a clear temporal
trend in any of the 4 regions.
MULTIVARIATE ANALYSES
Table4 gives the results of multivariate regression analy-
ses for model 1, in which the covariates were age, sex,
year of follow-up, and geographic area, and for model 2,
in which the covariates tumor subsite and type of diag-
nosis verification were added. In model 1, RER was 10%
higher in male patients and was about 2 and 21⁄2 times
higher, respectively, in the groups aged 55 to 64 years
and 75 years or older compared with the group aged 54
years or younger. Mortality was much lower during the
first year after diagnosis compared with later years; RER
was about 11⁄2 times higher for years 2 to 4 of follow-up
compared with the first year. The period of diagnosis was
Table 1. Registries Contributing Cases for the Present Study
and Number of Patients With 5-Year Follow-up Data
Registry
No. of
Cases Registry
No. of
Cases
United Kingdom Western European area
East Anglia 149 Bas Rhin 57
Mersey 146 Calvados Gen 32
Midlands 208 Eindhoven 49
Oxford 179 Geneva 21
Southwestern area 537 Latina 13
Thames 482 Mallorca 9
Trent 370 Navarra 15
Wales 200 Parma 22
Yorkshire 275 Ragusa 5
Nordic area Saarland 66
Denmark 547 Tarragona 7
Finland 350 Turin 33
Iceland 14 Tuscany 47
Norway 442 Varese 35
Sweden 808 Eastern European area
Cracow 51
Estonia 125
Slovakia 345
Slovenia 149
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neither associated with survival nor is it an interaction
with geographic area in any multiple regression models
(data not shown). There were differences in survival
among geographic areas (Table 4). Survival was similar
in the Nordic area (RER, 1.03; 95% confidence interval
[CI], 0.87-1.21) compared with the United Kingdom and
in the eastern European area (RER, 1.01; 95% CI, 0.82-
1.25) compared with the western European area. Sur-
vival was lower for the pooled western and eastern Eu-
ropean areas compared with the pooled UK and Nordic
areas (RER, 1.24; 95% CI, 1.09-1.41).
Model 2 shows that survival tended to be better for
clinically verified tumors compared with microscopi-
cally verified tumors, as expected because enucleated tu-
mors are typically larger at diagnosis. In addition, tu-
mors with unspecified ocular location (ICD-9 topography
code 190.9) were associated with much higher mortal-
ity (RER, 1.46; 95% CI, 1.19-1.79), which suggests that
this code is used for large tumors, for which the origin
from typical uveal subsites (ie, iris and ciliary body vs
choroid) is difficult or impossible to ascertain. This cod-
ing was more common in the United Kingdom (33.6%
of all tumors) compared with the other areas (7.1%-
13.3%). In this model, the difference between the United
Kingdom and western Europe reached statistical signifi-
cance (P=.01).
COMMENT
We analyzed the largest published series of uveal mela-
nomas to estimate relative survival based on 32
EUROCARE population-based cancer registries in 16 Eu-
ropean countries, enabling us to study the effect of demo-
graphic characteristics and geographic area on survival
as well as its temporal trend.
The 5-year relative survival rate was stable during the
study period and was higher in the UK and Nordic areas
compared with the western and eastern European areas.
Lower survival rates were found for older age, male sex,
and follow-up years 2 to 4. These results can be com-
pared with those of 3 population-based studies that in-
vestigated 5-year relative survival in patients with uveal
melanoma in the United States,1 Sweden,15 Denmark,16
and England and Wales (UK study)17 (Table 5). Al-
though the samples in the 3 European studies overlap
in part with our sample, the inclusion criteria differ, and
we suggest that a comparison is useful.
OVERALL 5-YEAR RELATIVE SURVIVAL
Five-year relative survival in the present study was close
to that of the 2 European studies15,16 and was lower than in
the US study1 owing to differences in the inclusion crite-
ria. The authors of the US study did not include melano-
mas with unspecified ocular location (ICD-9 code 190.9),
accounting for 31% of all cases of ocular melanoma in the
earliest period (1973-1977) to less than 5% in the recent
period of the study (1993-1997). However, there was in-
direct evidence from the present study and from an inci-
dence report based on this same cohort4 that this code was
probably used for large uveal melanomas that were diffi-
cult to ascribe to a specific subsite. Tumors with unspeci-
fied ocular location were included in the Danish study,16
whereasBergmanetal15 didnot includethembutperformed
an extensive search of hospital files to determine all inci-
dentmelanomas.Nevertheless,althoughbettersurvivalmight
have been the result, in part, of underascertainment of ad-
vanced cases in the US study as compared with the Euro-
pean studies, such a large difference is unlikely to be attrib-
utabletoonlythispotentialfactorbecauseinourstudy,5-year
relative survival was 70% for tumors located in the iris and
ciliary body (ICD-9 code 190.0) and was 68% for those lo-
cated inthechoroidandretina(ICD-9codes190.6and190-
5), which is still largely less than the relative survival in the
US study. The findings in the UK study17 confirm these ob-
servations; lack of inclusion of the unspecified site in the
UKstudy ledtoanestimateof5-year relativesurvival (72%)
that was similar to ours. The authors observed that the dif-
ferencesmaybeattributable, inpart, tohowcliniciansclas-
sify uveal melanoma and report to the cancer registries be-
causesurvivalintheUnitedStatesishigherthanintheUnited
Kingdom for most major cancers.
TEMPORAL DIFFERENCES IN SURVIVAL
No temporal trend for change in relative survival was de-
tected during our 12-year study, consistent with the re-
sults of the US,10 Danish,16 and UK17 studies. Singh and
Topham1 reported that increasing frequency of globe con-
servation in primary uveal melanoma has not led to im-
provement in survival. However, the stability of population-
Table 2. Five-Year Relative Survival Rates
Variable
No. of
Cases
5-Year Relative
Survival, %
(95% Confidence
Interval)
Overall 5788 68.9 (67.4-70.4)
Age, y
15-54 1681 79.0 (77.0-81.1)
55-74 2954 65.2 (63.2-67.3)
75 1153 58.8 (54.1-63.4)
Sex
Female 2892 69.3 (67.2-71.4)
Male 2896 68.5 (66.3-70.7)
Study period
1983-1985 1384 69.1 (66.0-72.2)
1986-1988 1455 69.2 (66.2-72.2)
1989-1991 1486 68.2 (65.2-71.2)
1992-1994 1463 69.1 (66.0-72.1)
Geographic region
United Kingdom 2546 70.5 (68.2-72.8)
Nordic area 2161 69.2 (66.7-71.7)
Western European area 411 63.3 (57.7-69.0)
Eastern European area 670 65.4 (60.9-69.8)
Microscopic verification
Yes 5113 67.9 (66.3-69.5)
No 675 76.7 (72.4-81.1)
Subsite (ICD-9 code)
Iris and ciliary body (190.0) 751 68.0 (63.8-72.2)
Choroid and retina (190.5-190.6) 4121 70.3 (68.6-72.1)
Unspecified ocular subsite (190.9) 916 63.0 (59.0-67.0)
Abbreviation: ICD-9, International Classification of Diseases, Ninth
Revision.
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based survival suggests that the equal efficacy of enucleation
and brachytherapy in the COMS,3 which was a random-
ized clinical trial, has been translated into similar effective-
ness when the eyeball-preserving technique was used in
differenthealthcare settings inEuropeand theUnitedStates.
Unlike the studies cited,Bergmanet al15 reportedan im-
provement in5-yearrelativesurvival inSweden(RER,0.58;
95% CI, 0.43-0.78) for 1980-1989 compared with 1960-
1969.Theyhypothesizedthatmoreindividualssoughtmedi-
caladviceearlierbecauseofdecreasingvisionorunderwent
eye screening in recent years. However, they observed that
incidencedecreasedduringthesameperiod15;thus,increased
survivalasaresultofearly tumordetection isunlikely.They
concluded that the reason for the improvement in survival
remainsunclear.ThefindingwasnotconfirmedintheDan-
ishstudy,which is similar tooursas far as sample size, race/
ethnicity, and temporal extension.1
Although our study was much shorter than other popu-
lation-based studies, we could exclude a trend of rela-
tive survival exceeding the interval −1.3% to 1% per
year on the basis of the width of the 95% CI of our esti-
mate. We confirm the finding of Bergman et al15 that peak
excess mortality occurs during years 2 to 4 after diagno-
sis. This could be owing to cases with metastatic mela-
noma at diagnosis, even if undetected.
DEMOGRAPHIC DIFFERENCES IN SURVIVAL
We have shown that 5-year relative survival in patients
with uveal melanoma decreased with increasing age at
diagnosis, as for most common cancers. This finding is
consistent with the findings in the Swedish,15 Danish,16
and UK17 cohorts.
There was also a difference between sexes in our study,
with male patients having 10% higher mortality. The lack
of difference in survival by sex at univariate compared with
multivariate analysis can be explained by confounding by
age because of a higher percentage of older women com-
pared with men. The statistical significance of the sex dif-
ference in survival is a new finding in population-based
studies. Better survival in female patients previously was
suggested in Sweden,15 Denmark,16 and the United King-
dom17; however, sex differences were not statistically sig-
nificant in those studies, possibly because they included
about half as many cases as in our study over a longer pe-
riod. The potential causes of a sex difference in survival
are unclear. No sex differences in survival were found in
the COMS,3,18 which is the largest randomized multi-
center trial on the treatment of uveal melanoma. The COMS
survival rates are adjusted for important individual tumor-
specific variables, in particular, maximum basal tumor di-
ameter, which, together with age, is the strongest predic-
tor of mortality. That no sex difference was found in the
COMS may suggest that a later diagnosis could cause lower
survival in men in population-based studies.
GEOGRAPHIC DIFFERENCES IN SURVIVAL
Theremaybemultipleexplanationsforthedifferencesfound
byusamongbroadEuropeanareas.Notonlycouldunknown
genetic or environmental factors affect mortality, but also
clinical factors such as late diagnosis might influence the
estimate of relative survival. Different treatment patterns
Table 3. Five-Year Relative Survival by Geographic Area Across Period of Diagnosis and Overall
Period of
Diagnosis
Geographic Region
Total,
No. (%)
United Kingdom,
No. (%)
Nordic Area,
No. (%)
Western European Area,
No. (%)
Eastern European Area,
No. (%)
1983-1985 612 (66.6) 522 (71.5) 86 (65.5) 164 (72.7) 1384 (69.1)
1986-1988 643 (73.7) 547 (66.2) 94 (65.9) 171 (64.0) 1455 (69.2)
1989-1991 672 (71.7) 527 (68.6) 113 (56.3) 174 (61.6) 1486 (68.2)
1992-1994 619 (69.7) 565 (70.4) 118 (66.6) 161 (63.7) 1463 (69.1)
Overall 2546 (70.5) 2161 (69.2) 411 (63.3) 670 (65.4) 5788 (68.9)
Table 4. Relative Excess Risk of Death: Model 1 vs Model 2
Variable
Relative Excess Risk
(No. [95% CI])
P
ValueModel 1 Model 2
Follow-up year .001
1 1 [Reference] 1 [Reference]
2 1.50 (1.14-1.96) 1.49 (1.11-1.98)
3 1.67 (1.28-2.17) 1.66 (1.26-2.19)
4 1.58 (1.12-2.23) 1.58 (1.10-2.27)
5 1.25 (0.86-1.81) 1.25 (0.85-1.83)
Age, categorical, y .001
15-54 1 [Reference] 1 [Reference]
55-74 1.84 (1.61-2.10) 1.81 (1.59-2.06)
75 2.45 (2.10-2.86) 2.41 (2.07-2.82)
Sex
Female 1 [Reference] 1 [Reference]
Male 1.10 (1.02-1.19) 1.11 (1.03-1.20)
Geographic region .001
United Kingdom 1 [Reference] 1 [Reference]
Nordic area 1.03 (0.87-1.21) 1.09 (0.94-1.25)
Western European area 1.25 (0.90-1.60) 1.34 (1.06-1.69)
Eastern European area 1.26 (1.05-1.52) 1.33 (1.14-1.56)
Linear trend per 4 years 0.99 (0.95-1.04) 1.00 (0.95-1.06)
Type of verificationa .16
Microscopic 1 [Reference]
Clinical or unknown 0.69 (0.41-1.17)
Subsite (ICD-9 code) .001
Ciliary body, retina,
choroid (190.0,
190.5, 190.6)
1 [Reference]
Unspecified (190.9) 1.46 (1.19-1.79)
Abbreviations: CI, confidence interval; ICD-9, International Classification of
Diseases, Ninth Revision.
aTumor subsite and type of diagnosis verification have been introduced in
model 2 as compared with model 1.
(REPRINTED) ARCH OPHTHALMOL / VOL 126 (NO. 10), OCT 2008 WWW.ARCHOPHTHALMOL.COM
1416
©2008 American Medical Association. All rights reserved.
Downloaded From:  by a London Sch of Hygiene & Tropical Medicine User  on 05/09/2018
mayhave influencedsurvival rates.Against thishypothesis
is the observation that enucleation and brachytherapy did
not produce different outcomes in the COMS.3
INCLUSION CRITERIA AND CASE DETECTION
IN POPULATION-BASED STUDIES
OF UVEAL MELANOMA
The issue of inclusion criteria was proved important when
the incidence of uveal melanoma was studied in registry-
basedresearch,ashasalsobeenrecentlypointedoutbyStang
et al.5 In the incidence study based on these same data,4 we
foundthattheinclusionofmelanomaswithunspecifiedocu-
lar location (ICD-9 topography code 190.9) decreased the
heterogeneityofincidenceratesamongregistriesintheUnited
Kingdom,wherethiscodingiscommon,andinEuropeover-
all. In the present study, melanomas with unspecified ocu-
lar location were associated with worse prognosis, which
isconsistentwiththehypothesis thatregistrarsusethiscode
for large tumors, the origin of which cannot be ascribed to
a specific uveal subsite. We recommend that further
population-based investigationsof survival inpatientswith
uveal melanoma be reported with the inclusion of tumors
withunspecified location(ICD-9code190.9).Althoughtu-
mors with unspecified location should be included in the
analysis,werecommendcautioninRERinterpretationwhen
adjustingforthisvariable.Forexample, theRERinthewest-
ernEuropeanareawasstatisticallysignificantcomparedwith
in the United Kingdom when adjusting for tumor subsite,
but the interpretation of this finding is unclear given the
large difference in the use of this code in the United King-
dom compared with continental Europe, which suggests
heterogeneity of diagnostic criteria.
In conclusion, 5-year relative survival remained stable
during the study period, a finding that confirms at the gen-
eralpopulation level that the increase inconservative therapy
during the years of the study did not negatively affect the
prognosis of the disease. However, survival rates did not
improve at the population level, which is the primary goal
of treatment of malignant tumors. We found differences
in survival rates between sexes and among European areas
that should be investigated in studies that take into ac-
count tumor characteristics at the individual level.
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cerRegistry,Prague);Finland:T.Hakulinen(FinnishCancer
Registry, Helsinki); France: G. He´delin (Bas-Rhin Cancer
Registry, Strasbourg), J. Mace´-Lesec’h (Calvados General
Cancer Registry, Caen), A. Danzon (Doubs Cancer Regis-
try, Besancon), B. Tretarre (He´rault Cancer Registry, Mont-
Table 5. Characteristics of Previous Population-Based Survival Studies on Uveal and Ocular Melanoma
Characteristic
Source
Singh and Topham,1 2003 Bergman et al,15 2002 Isager et al,16 2006 Burr et al,17 2007 Present Study
Geographic region United States Sweden Denmark England and Wales Europe
Sources of data and type
of study
SEER program database;
population-based study
Swedish Cancer Registry,
hospital files from the
2 centers performing
eye-sparing
treatments;
hospital-based study
Danish Cancer Registry;
population-based
study
Population-based
cancer registries
EUROCARE-based
study of survival
and care of cancer
patients;
population-based
study
Period of diagnosis 1973-1993 1960-1998 1943-1997 1986-2001 1983-1994
No. of cases 2054 2997 2504 2876 5788
Topographic inclusion
criteria: subsite
Choroid, iris, ciliary body Choroid, iris, ciliary body Ocular region, ie, eyeball;
orbit; lacrimal gland,
duct, or sac;
conjunctiva (excluding
skin melanoma)
Choroid, retina, iris,
ciliary body
Iris and ciliary body,
choroid, retina,
unspecified ocular
part
5-Year relative survival, % 77-84 70.1 67-71 72.4 68.9
Survival by sex Not reported In male patients, 12%
worse but not
statistically significant;
multivariate relative
survival in male vs
female patients,
0.88 (95% CI,
0.73-1.05)
In male patients,
6% worse but not
statistically significant;
5-year relative survival,
71% in male patients
vs 67% in female
patients
Better in women at 5
years (RER, 0.90
compared with
men) but not
statistically
significant
In male patients,
10% worse and
statistically
significant;
multivariate RER
1.10 (95% CI,
1.02-1.19
Survival by period Stable Improved from
1980-1989 vs
1960-1969
Stable Stable Stable
Abbreviations: CI, confidence interval; EUROCARE, European Cancer Registry; RER, relative excess risk; SEER, National Cancer Institute Surveillance Epidemiology
and End Results.
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brucken); Iceland:L. Tryggvadottir (Icelandic Cancer Reg-
istry, Reykjavik); Italy: F. Berrino, C. Allemani, P. Baili, L.
Ciccolallo, P. Crosignani, G. Gatta, A. Micheli, M. Sant, E.
Taussig, and S. Sowe (Istituto Nazionale per lo Studio e la
Cura dei Tumori, Lombardy Cancer Registry, Milano), S.
Ferretti (Ferrara Cancer Registry, Ferrara), V. Ramazzotti
and M. C. Cercato (Latina Cancer Registry, Roma), M.
Vercelli and A. Quaglia (Liguria Region Cancer Registry–
Department of Oncology, Biology, and Genetics [DOBIGO]
of the University of Genova, Genova), F. Pannelli (Mac-
erata Cancer Registry, Camerino), M. Federico and M. E.
Artioli (Modena Cancer Registry, Modena), V. De Lisi and
L. Servente (Parma Cancer Registry, Parma), R. Zanetti and
S. Patriarca (Piedmont Cancer Registry, Torino), L. Gafà
and R. Tumino (Ragusa Cancer Registry, Ragusa), F. Falcini
(Romagna Cancer Registry, Forli), M. Budroni (Sassari Can-
cer Registry, Sassari), E. Paci and E. Crocetti (Tuscan Can-
cer Registry, Firenze), P. Zambon and S. Guzzinati (Vene-
tian Cancer Registry, Padova), and R. Capocaccia, E.
Carrani, R. De Angelis, P. Roazzi, M. Santaquilani, A. Tavilla,
F. Valente, and A. Verdecchia (Istituto Superiore di Sanità,
Roma); Malta: M. Dalmas (Malta National Cancer Regis-
try, Valletta);Norway:F. Langmark and A. Andersen (Can-
cer Registry of Norway, Institute of Population-based Can-
cerResearch,Oslo);Portugal: P.Pinheiro (SouthernPortugal
Cancer Registry, Lisboa);Poland: J. Rachtan (Cracow Can-
cer Registry, Cracow) and M. Bielska–Lasota, Z.
Wronkowski, and M. Zwierko (Warsaw Cancer Registry,
Warsaw); Slovakia: I. Plesˇko and A. Obsitnı´kova´ (Na-
tional Cancer Registry of Slovakia, Bratislava); Slovenia:V.
Pompe–Kirn and M. Primic-Zˇakelj (Cancer Registry of Slo-
venia, Ljubljana);Spain: I. Izarzugaza (Basque Country Can-
cer Registry, Vitoria-Gasteiz), C. Martinez-Garcia (Granada
Cancer Registry, Granada), I. Garau (Mallorca Cancer Reg-
istry, Palma de Mallorca), C. Navarro and M. D. Chirlaque
(Murcia Cancer Registry, Murcia), E. Ardanaz and C.
Moreno (Navarra Cancer Registry, Pamplona, Navarra), and
J. Galceran (Tarragona Cancer Registry, Reus); Sweden: L.
Barlow (Cancer Registry of Sweden, Stockholm) and T.
Möller (Southern Swedish Regional Tumour Registry, Lund
University Hospital, Lund); Switzerland: G. Jundt (Basel
Cancer Registry, Basel) and J. M. Lutz and C. Bouchardy
(Geneva Cancer Registry, Geneva); the Netherlands: J. W.
W. Coebergh (Eindhoven Cancer Registry, Eindhoven) and
O. Visser (Amsterdam Cancer Registry, Amsterdam);
England: S. Godward (East Anglian Cancer Registry, Cam-
bridge), M. P. Coleman (London School of Hygiene and
Tropical Medicine, London), E. M. I. Williams (Mersey-
side and Cheshire Cancer Registry, Liverpool), D. Forman
(Northern and Yorkshire Cancer Registry and Informa-
tion Service, Leeds), M. J. Quinn (Office for National Sta-
tistics, London), M. Roche and S. Edwards (Oxford Can-
cer Intelligence Unit, Oxford), C. Stiller (Childhood Cancer
Research Group, Oxford), J. Verne (South West Cancer In-
telligence Services, Bristol), H. Møller and J. Bell (Thames
Cancer Registry, London), H. Botha (Trent Cancer Regis-
try, Sheffield), and G. Lawrence (West Midlands Cancer
Intelligence Unit, Birmingham); Scotland: R. Black (Scot-
tish Cancer Intelligence Unit, Edinburgh); Wales: J. A.
Steward (Welsh Cancer Intelligence and Surveillance Unit,
Cardiff).
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